ASH 2018 | iFCG for the frontline treatment of IGHV-mutated CLL: trial update
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
In this interview, Nitin Jain, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the results of the Phase II trial (NCT02629809) assessing the combination of ibrutinib, fludarabine, cyclophosphamide and obinutuzumab (iFCG) as a front-line therapy for patients with IGHV-mutated chronic lymphocytic leukemia (CLL). As a result of the increased efficacy of this combination vs. FCR, Dr Jain explains how this reduces the requirement for chemotherapy and subsequent toxicity, before revealing the high rate of undetectable MRD with the iFCG regimen. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up